



GlaxoSmithKline

November 4, 2011

Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C – 1, Block - G
Bandra Kurla Complex, Bandra (E)
Mumbai – 400 051

GlaxoSmithKline
Consumer Healthcare Ltd.

DLF Plaza Tower
DLF City Phase-1
Gurgaon 122002
Haryana, India

Tel. (0124) 2540700 / 4057700
Fax. (0124) 2540720-21
www.gsk.com

Dear Sir,

Subject: Unaudited Financial Results for the Quarter ended 30 September 2011

We would like to inform you that the Board of Directors at a meeting held on Friday, 4 November 2011 at 12.00 Noon at DLF Plaza Tower, DLF City, Phase - I, Gurgaon 122 002, have, inter alia, considered and taken on record the unaudited financial results for the quarter ended 30 September 2011. We are enclosing a copy of the Unaudited financial results for the quarter ended 30 September 2011 along with the "Limited Review" Certificate, issued by the Auditors for the review done by them, for your records.

Also take note that the Board of Directors has re-appointed Mr. Zubair Ahmed as Managing Director of the Company for the period from January 1, 2012 to May 31, 2013 as a Nominee of Horlicks Ltd., the promoters of the Company. Mr. Zubair Ahmed's terms of appointment and remuneration are subject to the approval of the shareholders.

The above may please be taken as our intimation under Clause 41 and other relevant clauses of the Listing Agreement.


Thanking you.

Yours faithfully,
For GlaxoSmithKline
Consumer Healthcare Limited


Ramakrishnan Subramanian
Director - Finance

GLAXOSMITHKLINE CONSUMER HEALTHCARE LIMITED
UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED SEPTEMBER 30, 2011


PARTICULARS	QUARTER ENDED (UNAUDITED)			NINE MONTHS ENDED (UNAUDITED)			ACCOUNTING YEAR (AUDITED) (Rs. in Lakhs)
	Sep 30, 2011	Sep 30, 2010	Sep 30, 2011	Sep 30, 2011	Sep 30, 2010	December 31, 2010	
1. (a) Net Sales / Income from Operations	7,20,07	6,12,58	20,83,46	20,83,46	17,98,36	23,06,12	
(b) Other Operating Income	24,53	20,44	62,43	62,43	51,20	67,63	
Total Income	7,44,60	6,33,02	21,45,89	21,45,89	18,49,56	23,73,75	
2. Expenditure:							
a) (Increase) / Decrease in Stock in Trade and Work in Progress	(5,38)	(13,34)	28,34	28,34	24,16	(29,80)	
b) Consumption of Raw Materials	1,80,75	1,50,08	5,06,30	5,06,30	4,40,48	5,85,21	
c) Consumption of Packing Materials	64,99	52,32	1,70,67	1,70,67	1,40,93	1,93,13	
d) Purchase of traded goods	32,55	38,85	1,03,30	1,03,30	80,97	1,16,37	
e) Employee's Cost	66,27	58,25	1,96,67	1,96,67	1,68,77	2,29,66	
f) Advertising & Promotion	1,19,62	1,07,77	3,23,18	3,23,18	2,81,18	3,70,63	
g) Depreciation / Amortisation	11,65	9,96	33,89	33,89	28,81	39,71	
h) Other Expenditure	1,43,27	1,23,58	3,91,67	3,91,67	3,43,57	4,64,20	
i) Total Expenditure (a+b+c+d+e+f+g+h)	6,13,72	5,27,47	17,54,02	17,54,02	15,08,87	19,69,11	
3. Profit from Operations before Other Income, Interest & Exceptional Items (1-2)	1,30,88	1,05,55	3,91,87	3,91,87	3,40,69	4,04,64	
4. Other Income	23,11	12,96	53,67	53,67	33,05	49,76	
5. Profit before Interest & Exceptional Items (3+4)	1,53,99	1,18,51	4,45,54	4,45,54	3,73,74	4,54,40	
6. Interest	1,03	73	2,59	2,59	1,92	2,60	
7. Profit after Interest but before Exceptional Items (5-6)	1,52,96	1,17,78	4,42,95	4,42,95	3,71,82	4,51,80	
8. Exceptional Items	-	-	-	-	-	-	
9. Profit (+) / Loss (-) from Ordinary Activities Before Tax (7+8)	1,52,96	1,17,78	4,42,95	4,42,95	3,71,82	4,51,80	
10. Tax expense	49,93	39,21	1,46,84	1,46,84	1,25,34	1,51,95	
11. Net Profit (+) / Loss (-) from Ordinary Activities after Tax (9-10)	1,03,03	78,57	2,96,11	2,96,11	2,46,48	2,99,85	
12. Extraordinary Items (net of tax expense)	-	-	-	-	-	-	
13. Net Profit (+) / Loss (-) for the period (11-12)	1,03,03	78,57	2,96,11	2,96,11	2,46,48	2,99,85	
14. Paid Up Equity Share Capital	42,06	42,06	42,06	42,06	42,06	42,06	
- Face Value of Equity Shares-Rs.	10	10	10	10	10	10	
15. Reserves excluding Revaluation Reserves as per Balance Sheet of the previous accounting year						9,17,98	
16. Earnings Per Share (EPS) - Rs.							
(a) Basic and diluted EPS before Extraordinary items for the period and for the previous year (not annualized)						71.30	
(b) Basic and diluted EPS after Extraordinary items for the period and for the previous year (not annualized)						71.30	
17. Public Shareholding							
- Number of Shares	2,39,03,295	2,39,03,295	2,39,03,295	2,39,03,295	2,39,03,295	2,39,03,295	
- Percentage of Shareholding	56.84	56.84	56.84	56.84	56.84	56.84	
18. Promoters and Promoter Group Shareholding							
a) Pledged/Encumbered	-	-	-	-	-	-	
- Number of shares	-	-	-	-	-	-	
- Percentage of shares (as a % of the total shareholding of Promoter and Promoter Group)	-	-	-	-	-	-	
b) Non-encumbered	-	-	-	-	-	-	
- Percentage of shares (as a % of the total share capital of the Company)	-	-	-	-	-	-	
- Number of shares	1,81,52,243	1,81,52,243	1,81,52,243	1,81,52,243	1,81,52,243	1,81,52,243	
- Percentage of shares (as a % of the total shareholding of Promoter and Promoter Group)	100.00	100.00	100.00	100.00	100.00	100.00	
- Percentage of shares (as a % of the total share capital of the Company)	43.16	43.16	43.16	43.16	43.16	43.16	


 Place: Hyderabad
 Date: 10/10/2011
 For: GLAXOSMITHKLINE CONSUMER HEALTHCARE LIMITED
 By: Authorized Signatory

GLAXOSMITHKLINE CONSUMER HEALTHCARE LIMITED
UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED SEPTEMBER 30, 2011

NOTES

- (1) The Company's nutritional business is India focused and in a single business and geographical segment. Accordingly segment information is not applicable.
- (2) The Company received 66 investor complaints during the quarter ended September 30, 2011 which were duly resolved by the end of the quarter. There were no investor complaints pending at the beginning and at the end of the quarter.
- (3) The unaudited financial results for the quarter ended September 30, 2011 have been reviewed by the Audit Committee of the Board and approved by the Board of Directors of the Company at its meeting held on November 4, 2011. The Limited Review for the unaudited financial results for the quarter ended September 30, 2011, as required under Clause 41 of the Listing Agreement has been completed by the statutory auditors.
- (4) Figures for the previous period have been regrouped/reclassified wherever necessary, to conform to the current period's classification.



REGD. OFFICE: PATIALA ROAD, NABHA 147201 (PUNJAB).
HEAD OFFICE: DLF PLAZA TOWER, DLF CITY PHASE I,
GURGAON - 122002, HARYANA.

ON BEHALF OF THE BOARD

Zubair Ahmed

ZUBAIR AHMED
MANAGING DIRECTOR

GURGAON
November 4, 2011

The Board of Directors,
GlaxoSmithKline Consumer Healthcare Limited,
DLF Plaza Tower
DLF City Phase-I
Gurgaon 122002
Haryana, India

1. We have reviewed the accompanying 'Unaudited Financial Results for the quarter ended September 30, 2011 in which are included the results for the quarter ended September 30, 2011 (the "Statement") of GlaxoSmithKline Consumer Healthcare Limited, except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the Management but have neither been reviewed nor been audited by us. The Statement has been prepared by the Company pursuant to Clause 41 of the Listing Agreement with the Stock Exchanges in India, which has been initialled by us for identification purposes. This Statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement.
3. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
4. We have only traced the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' in the Statement from the disclosures made by the Management and are, therefore, not expressing a review opinion thereon.
5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with the applicable Accounting Standards notified pursuant to the Companies (Accounting Standards) Rules, 2006 as per Section 211(3C) of the Companies Act, 1956 and other recognised accounting practices and policies, and has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Price Waterhouse.
Firm Registration Number: 301112E
Chartered Accountants

Gurgaon
November 04, 2011

Usha Rajeev,
Partner.
Membership Number: F 087191

34
W